keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial

keyword
https://www.readbyqxmd.com/read/29342309/prognostic-power-of-a-tumor-differentiation-gene-signature-for-bladder-urothelial-carcinomas
#1
Qianxing Mo, Fotis Nikolos, Fengju Chen, Zoe Tramel, Yu-Cheng Lee, Kazukuni Hayashi, Jing Xiao, Jianjun Shen, Keith Syson Chan
Background: Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of a prognostic tool that can guide decision-making is crucial for improving clinical management of bladder urothelial carcinomas. Methods: Tumor grade is defined by pathologic evaluation of tumor cell differentiation, and it often associates with clinical outcome...
January 12, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29341833/immune-modified-response-evaluation-criteria-in-solid-tumors-imrecist-refining-guidelines-to-assess-the-clinical-benefit-of-cancer-immunotherapy
#2
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S Chen, Jedd D Wolchok
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29341477/evidence-based-adequacy-criteria-for-instrumented-urine-cytology-using-cytospin-preparations
#3
Andrew A Renshaw, Edwin W Gould
Cytospin preparations of instrumented urine cytology specimens with less than 10 urothelial cells or more than 50 urothelial cells/10 hpfs are both associated with significantly increased false negative rates compared to cases with 10-49 urothelial cells/10 hpfs.
January 16, 2018: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29340094/can-urologists-introduce-the-concept-of-oligometastasis-for-metastatic-bladder-cancer-after-total-cystectomy
#4
Koichiro Ogihara, Eiji Kikuchi, Keitaro Watanabe, Ryohei Kufukihara, Yoshinori Yanai, Kimiharu Takamatsu, Kazuhiro Matsumoto, Satoshi Hara, Masafumi Oyama, Tetsuo Monma, Takeshi Masuda, Shintaro Hasegawa, Mototsugu Oya
We investigated whether the concept of oligometastasis may be introduced to the clinical management of metastatic bladder cancer patients. Our study population comprised 128 patients diagnosed with metastatic bladder cancer after total cystectomy at our 6 institutions between 2004 and 2014. We extracted independent predictors for identifying a favorable. Occurrence that fulfilled all 4 criteria which were independently associated with cancer-specific death was defined as oligometastasis: a solitary metastatic organ; number of metastatic lesions of 3 or less; the largest diameter of metastatic foci of 5cm or less; and no liver metastasis...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29338914/prophylactic-antibiotics-following-radical-cystectomy-reduces-urinary-tract-infections-and-readmission-for-sepsis-from-a-urinary-source
#5
Ryan P Werntz, Ann Martinez-Acevedo, Hamed Amadi, Ryan Kopp, Jeffrey La Rochelle, Theresa Koppie, Christopher Amling, Kamran P Sajadi
INTRODUCTION: Urinary tract infections (UTI) and sepsis contribute significantly to the morbidity associated with cystectomy and urinary diversion in the first 30 days. We hypothesized that continuous antibiotic prophylaxis decreased UTIs in the first 30 days following radical cystectomy. METHODS: Patients with urothelial carcinoma of the bladder who underwent a radical cystectomy with urinary diversion for bladder cancer at Oregon Health and Science University from January 2014 to May 2015 were included in the study...
January 12, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29338913/discrepancies-in-staging-treatment-and-delays-to-treatment-may-explain-disparities-in-bladder-cancer-outcomes-an-update-from-the-national-cancer-data-base-2004-2013
#6
Adam B Weiner, Mary-Kate Keeter, Adarsh Manjunath, Joshua J Meeks
INTRODUCTION: We sought to characterize national disparities in the diagnosis of advanced stage bladder cancer. Among patients with advanced disease, we explored disparities in overall survival, treatment, and time to treatment. METHODS AND MATERIALS: We queried the National Cancer Data Base for patients diagnosed with bladder urothelial carcinoma. We used multivariable logistic regression to assess the association between covariates and diagnosis of advanced disease (AJCC stage III-IV)...
January 12, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29336836/current-status-of-tissue-engineering-applied-to-bladder-reconstruction-in-humans
#7
C Gasanz, C Raventós, J Morote
CONTEXT AND OBJECTIVE: Bladder reconstruction is performed to replace or expand the bladder. The intestine is used in standard clinical practice for tissue in this procedure. The complications of bladder reconstruction range from those of intestinal resection to those resulting from the continuous contact of urine with tissue not prepared for this contact. In this article, we describe and classify the various biomaterials and cell cultures used in bladder tissue engineering and reviews the studies performed with humans...
January 11, 2018: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/29336367/reduction-of-tat-interacting-protein-30-expression-could-be-a-prognostic-marker-in-bladder-urothelial-cancer
#8
Ye-Ping Li, Jian-Fang Zhu, Ka-Te Huang, Rong-Rong Wang, Bing Cai, Hui Xie, Hong-De Chen
BACKGROUND: Tat-interacting protein 30 (TIP30) has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer (BUC) has not been investigated. Therefore, herein, we investigated the expression of TIP30 protein in BUC and normal bladder mucosa and the clinical significance of TIP30 expression in the prognosis of BUC. METHODS: We reviewed data from 79 cases of BUC and 15 adjacent tissue samples from 79 patients treated at our institution between 2004 and 2007...
January 20, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29335525/urothelial-cancer-optimizing-and-integrating-cisplatin-based-chemotherapy-across-the-disease-spectrum
#9
Jay D Raman
No abstract text is available yet for this article.
January 16, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29334289/the-extracellular-matrix-degrading-protein-adamts5-is-expressed-in-the-nuclei-of-urothelial-cells-in-healthy-rats
#10
Dick Delbro, Lena Hallsberg, Ralph Peeker, Nikolai Scherbak, Magnus Fall, Rebecka Arnsrud Godtman
OBJECTIVE: The aim of this study was to investigate whether protein expression of the extracellular matrix-degrading protease ADAMTS5 can be demonstrated in the urinary bladder of healthy rats, and, if so, to determine the localization of this enzyme. MATERIALS AND METHODS: The experiments were conducted with eight inbred male Sprague-Dawley rats. Immunohistochemistry was used to investigate the expression of ADAMTS5 in the urinary bladder. Negative controls were established by either excluding the primary antibody or applying the antibody after it had been preabsorbed with its immunogenic peptide...
January 15, 2018: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/29334244/evolving-concepts-and-use-of-immunohistochemical-biomarkers-in-flat-non-neoplastic-urothelial-lesions-who-2016-classification-update-with-diagnostic-algorithm
#11
Francesca Sanguedolce, Matteo Brunelli, Alessandro D'Amuri, Beppe Calò, Vito Mancini, Giuseppe Carrieri, Luigi Cormio
CONTEXT: The classification of flat non-neoplastic urothelial lesions has been evolved through the years in the attempt to better define a spectrum of morphologic entities with somewhat overlapping features. Differentiating these lesions is important because of differences in patient management and clinical outcome. Materials and methods and objective: A systematic review of the literature has been carried out in order to (1) assess the most striking clinical features of each lesion, and (2) identify those morphological traits and immunophenotypical markers which may aid in the differential diagnosis...
January 15, 2018: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/29333509/rate-and-association-of-lower-urinary-tract-infection-with-recurrence-after-transurethral-resection-of-bladder-tumor
#12
Byung Soo Kim, Bum Sik Tae, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
Purpose: To evaluate the rate of pyuria and bacteriuria after transurethral resection of bladder tumor (TURBT). Materials and Methods: We retrospectively evaluated data obtained from 363 patients who underwent TURBT between October 2012 and December 2013 at Seoul National University Hospital. Urinalysis and urine culture were assessed at 3, 6, 12, and 24 months postoperatively. Primary endpoint was the rate of bacteriuria (≥105/mL in a midstream) and pyuria (white blood cells ≥5/high-power field)...
January 2018: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/29331216/chemoimmunotherapy-in-metastatic-urothelial-carcinoma
#13
EDITORIAL
Daniel M Geynisman, Phillip H Abbosh, Elizabeth R Plimack, Matthew Zibelman
No abstract text is available yet for this article.
January 10, 2018: European Urology
https://www.readbyqxmd.com/read/29330759/-autoimmune-reactions-to-immune-checkpoint-inhibitors
#14
REVIEW
W Pönisch, R Alten, C Baerwald
Immune checkpoint inhibitors (ICI) have dramatically changed the face of cancer treatment and are gaining in importance. The ICIs have now been approved for the treatment of advanced cancers, including melanoma, non-small-cell and small cell lung cancers, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancers and urothelial carcinoma and further indications are to be expected. The organs most affected by an autoimmune reaction are the intestines, the musculoskeletal system, skin, endocrine organs, the liver and the lungs...
October 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29330720/dialysis-increases-the-risk-of-bladder-recurrence-in-patients-with-upper-tract-urothelial%C3%A2-cancer-a-population-based-study
#15
Ming-Yen Lin, Wei-Ming Li, Chun-Nung Huang, Huei-Lan Lee, Sheng-Wen Niu, Li-Tzong Chen, Wen-Jeng Wu, Shang-Jyh Hwang
BACKGROUND: The relation of dialysis to tumor recurrence in patients with upper tract urothelial cancer (UTUC) is unknown; however, a limited number of small-scale studies suggest that patients with renal diseases prior to UTUC are more likely to exhibit bladder recurrence. We performed a population-based analysis to determine the effect of dialysis on bladder recurrence for patients with UTUC. METHODS: This retrospective cohort study included patients diagnosed with UTUC (2002-2007) from the Taiwan National Cancer Registry and divided them into two groups-dialysis and non-dialysis groups...
January 12, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29329894/neoadjuvant-dose-dense-mvac-versus-gc-in-patients-with-ct3-4an0m0-bladder-cancer-treated-with-radical-cystectomy
#16
Homayoun Zargar, Jay B Shah, Bas W van Rhijn, Siamak Daneshmand, Trinity J Bivalacqua, Philippe E Spiess, Peter C Black, Wassim Kassouf
BACKGROUND: Level I evidence supports the utility of neoadjuvant cisplatin-based chemotherapy (NAC) for muscle invasive bladder cancer (BCa). Since dose dense (ddMVAC) has mostly replaced traditional MVAC, we aimed to compare pathological response and survival rates in patients with locally advanced BCa receiving NAC with ddMVAC versus GC. METHODS: We retrospectively reviewed records of patients with urothelial cancer who received NAC and underwent cystectomy at 20 contributing institutions from 2000-2015...
January 9, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29329444/prevention-of-ivr-a-need-for-investigation
#17
Idir Ouzaid, Evanguelos Xylinas
Intravesical recurrence (IVR) after RNU for UTUC is a frequent event, occurring in 20-50% of patients, mostly in the first postoperative year. Several retrospective studies have shown that predictors of IVR include clinical characteristics, surgical features and as well pathological characteristics (previous history of bladder cancer, pathological stage, lymph node involvement, cis, endoscopic distal ureter, etc.) management. Two prospective studies provide level I evidence for the safety and efficacy of intravesical single postoperative chemotherapy for patients treated with radical nephroureterectomy (RNU) for UTUC in order to prevent IVR...
January 10, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29328452/hif%C3%A2-1%C3%AE-%C3%A2-induced-upregulation-of-lncrna-uca1-promotes-cell-growth-in-osteosarcoma-by-inactivating-the-pten-akt-signaling-pathway
#18
Tengfei Li, Yang Xiao, Tunsheng Huang
Increasing evidence indicates that long non‑coding RNAs (lncRNAs) play an important role in multiple biological processes including cell growth, differentiation, proliferation and invasion. Urothelial carcinoma associated 1 (UCA1) is a highly conserved nuclear ncRNA and a key regulator of cell proliferation and apoptosis in several types of cancers. However, its role in osteosarcoma progression is not well known. In the present study, we aimed to determine the biological role of UCA1 in osteosarcoma progression...
January 3, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29325739/anti-programmed-cell-death-1-ligand-1-pd-1-pd-l1-antibodies-for-the-treatment-of-urothelial-carcinoma-state-of-the-art-and-future-development
#19
REVIEW
Thomas Powles, Andrea Necchi, Galit Rosen, Subramanian Hariharan, Andrea B Apolo
Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. This review reports key findings from completed and ongoing clinical trials that highlight the potential of PD-1/PD-L1 blockade in urothelial carcinoma. A literature search was performed of PubMed, Embase, ClinicalTrials...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29323757/differentiation-associated-urothelial-cytochrome-p450-oxidoreductase-predicates-the-xenobiotic-metabolising-activity-of-luminal-muscle-invasive-bladder-cancers
#20
Simon C Baker, Volker M Arlt, Radek Indra, Madeleine Joel, Marie Stiborova, Ian Eardley, Niaz Ahmad, Wolfgang Otto, Maximilian Burger, Peter Rubenwolf, David H Phillips, Jennifer Southgate
Extra-hepatic metabolism of xenobiotics by epithelial tissues has evolved as a self-defence mechanism but has potential to contribute to the local activation of carcinogens. Bladder epithelium (urothelium) is bathed in excreted urinary toxicants and pro-carcinogens. This study reveals how differentiation affects cytochrome P450 (CYP) activity and the role of NADPH:P450 oxidoreductase (POR). CYP1A1 and CYP1B1 transcripts were inducible in normal human urothelial (NHU) cells maintained in both undifferentiated and functional barrier-forming differentiated states in vitro...
January 11, 2018: Molecular Carcinogenesis
keyword
keyword
4084
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"